Neuroscientific Biopharmaceuticals
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 3.8K
- Shares on issue
- 389.719M
Neuroscientific Biopharmaceuticals (NSB) Short Interest
Neuroscientific Biopharmaceuticals (ASX:NSB) had 0.00% of shares reported as short positions as of 3 July 2026, representing 3,800 shares. Neuroscientific Biopharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Neuroscientific Biopharmaceuticals
NeuroScientific Biopharmaceuticals Ltd is an Australian biotechnology company focused on developing novel stem cell technologies for immune-mediated inflammatory diseases. Their patented StemSmart™ technology aims to enhance the safety and efficacy of mesenchymal stem cell (MSC) therapies, targeting conditions like Crohn's disease. The company is currently prioritizing a special access program for fistulising Crohn’s disease and plans to advance to clinical trials.
Company profile →Neuroscientific Biopharmaceuticals (ASX:NSB) has 0.00% of its shares on issue reported as short positions as of 3 July 2026, or about 3,800 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. NSB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads NSB today
- Zanger BreakoutWatchScore 25rank 966 of 1942
- CAN SLIMWatchScore 10rank 1099 of 1541
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 25rank 560 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
NSB fundamentals
In the year to 30 Jun 2026, Neuroscientific Biopharmaceuticals (ASX:NSB) recorded revenue of A$629.4K and a net loss after tax of A$4.7M. A year earlier it recorded revenue of A$166.1K and a net loss after tax of A$1.8M. Year-on-year growth: revenue +279.0% (FY). Net margin −745.7%, return on equity −29.7% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest NSB news
All news- NeuroScientific Biopharmaceuticals Secures Unanimous Support for All Five AGM Resolutions on 15 October 2026, Including Company Name Change
kalkine · 15 Oct 2026
- NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
theage · 13 Oct 2026
- US FDA Provides Positive Feedback on Planned Phase 2 Trial
asx · 12 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss NSB
Start a research thread or post the first pulse update